PRESS RELEASE | Hampton, UK / Basel, Switzerland, March 01, 2022
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a development and manufacturing pipeline agreement with Versameb AG, an innovative pre-clinical stage company focused on discovering and developing ground-breaking RNA-based therapeutics.
PRESS RELEASE | Basel, Switzerland, February 24, 2022
Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, today announces the formation of an Advisory Board comprised of industry leaders in urology. These include Professor Roger Dmochowski of Vanderbilt University, Professor Margot Damaser of the Cleveland Clinic Lerner College of Medicine, and Assistant Professor Frédéric Birkhäuser of St. Anna and Hirslanden Clinic Lucerne.
PRESS RELEASE | Basel, Switzerland, February 17, 2022
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its Chief Scientific Officer, Friedrich Metzger will be presenting data on the Company’s mRNA engineering technology and lead therapeutic candidate, VMB-100, at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) 2022 Winter Meeting, taking place on 22-26 February 2022 in San Diego, California.
PRESS RELEASE | Basel, Switzerland, January 5, 2022
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that it will be attending Biotech Showcase: The Investor Conference for Innovators on the 10-12 January 2022. The Versameb team will be attending virtually.
PRESS RELEASE | Basel, Switzerland, November 4, 2021
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, today announces that its Chief Scientific Officer, Friedrich Metzger, will be presenting data on its mRNA engineering technology and lead therapeutic candidate, VMB-100, at the 9th International mRNA Health Conference taking place on 9th and 10th November 2021 in Berlin.
PRESS RELEASE | Basel, Switzerland, October 4, 2021
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, today announces its participation in the 21st Annual Biotech in Europe Forum organized by SACHS Associates taking place virtually 7th-8th October 2021.
PRESS RELEASE | Basel, Switzerland, March 11, 2021
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, announces that its management team will be presenting at / attending the following virtual conferences.
PRESS RELEASE | Basel, Switzerland, January 8, 2021
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, announces the appointment of Dr Klaas Zuideveld as Chief Executive Officer (CEO). Prof Friedrich Metzger will move back to the role of Chief Scientific Officer (CSO) to focus on developing Versameb’s innovative VERSagile RNA platform to enhance and combine therapeutic protein expression and cellular targeting, optimizing and tailoring first-in-class RNA therapeutics for hard to treat diseases.
PRESS RELEASE | Basel, Switzerland, July 15, 2020
Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer effective May 1 to advance its lead molecule into clinical development. Versameb is engaged in the discovery and development of next-generation RNA-based drugs using its proprietary VERSagile technology platform.
PRESS RELEASE | Basel, Switzerland, October 17, 2019
Versameb AG, a Swiss biopharmaceutical company, announced today the successful closing of a CHF 6.4 million Seed C financing round, bringing the total capital raised to date to CHF 11.8 million. Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKLearn moreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, you cannot refuse them without impacting how our site functions. You can block or delete them by changing your browser settings and force blocking all cookies on this website.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visist to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy